Significant Ownership of Affinity Asset Advisors, LLC

Signature - Title
/s/ Andrew Weinstein - Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Affinity Asset Advisors, LLC.

Notify me when Affinity Asset Advisors, LLC files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Affinity Asset Advisors, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
IBIO iBio, Inc. Common Stock, par value $0.001 per share 10% $2,508,633 2,181,420 Affinity Asset Advisors, LLC 19 Aug 2025
OVID Ovid Therapeutics Inc. Common Stock, par value $0.001 per share 9% $16,158,391 12,149,166 Affinity Asset Advisors, LLC 11 Dec 2025
KPTI Karyopharm Therapeutics Inc. Common Stock, par value $0.0001 per share 7.8% $2,849,521 664,224 Affinity Healthcare Fund, LP 03 Apr 2025
STRO SUTRO BIOPHARMA, INC. Common Stock, par value $0.001 per share 7.8% $5,717,348 6,583,772 Affinity Healthcare Fund, LP 16 Oct 2025
LXEO Lexeo Therapeutics, Inc. Common Stock, par value $0.0001 per share 7.8% $20,069,464 4,252,005 Affinity Healthcare Fund, LP 28 May 2025
AVTX Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share 7.6% $12,789,018 +$5,788,795 1,006,217 +83% Affinity Healthcare Fund, LP 30 Sep 2025
NXTC NextCure, Inc. Common Stock, par value $0.001 per share 7.2% $1,122,510 191,882 Affinity Healthcare Fund, LP 30 Sep 2025
FBRX Forte Biosciences, Inc. Common Stock, par value $0.001 per share 6.9% $16,437,344 862,400 Affinity Asset Advisors, LLC 17 Dec 2025
VTYX Ventyx Biosciences, Inc. Common Stock, par value $0.0001 per share 5.7% $4,909,097 4,057,105 Affinity Healthcare Fund, LP 22 May 2025
VRCA Verrica Pharmaceuticals Inc. Common Stock, $0.0001 par value per share 5.5% $3,421,746 884,172 Affinity Asset Advisors, LLC 25 Nov 2025
INZY Inozyme Pharma, Inc. Common Stock, par value $0.0001 per share 2.9% $2,203,898 1,867,710 Affinity Healthcare Fund, LP 20 May 2025

Schedules 13D/G Reported by Affinity Asset Advisors, LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.